Marksans Pharma Limited (IN:MARKSANS)
:MARKSANS
Want to see IN:MARKSANS full AI Analyst Report?
MARKSANS Stock Chart & Stats
₹182.05
-₹6.40(-2.21%)
At close: 4:00 PM EST
₹182.05
-₹6.40(-2.21%)
Day’s Range― - ―
52-Week Range₹155.50 - ₹270.60
Previous CloseN/A
Volume681.00K
Average Volume (3M)99.03K
Market Cap
₹111.93B
Enterprise Value₹105.10B
Total Cash (Recent Filing)₹6.71B
Total Debt (Recent Filing)₹3.32B
Price to Earnings (P/E)26.8
Beta1.33
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)7.77
Shares Outstanding453,163,760
10 Day Avg. Volume119,310
30 Day Avg. Volume99,030
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.35
Price to Sales (P/S)2.41
P/FCF Ratio20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.33
Revenue Forecast (FY)₹34.41B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained multi-year top-line growth indicates successful product penetration and geographic diversification in generics. A steady revenue base supports investments in scale, regulatory compliance and new product introductions, reducing reliance on any single market or short-term pricing cycles.
Margin DurabilityConsistent mid-teens net margins reflect structural pricing power, cost control and operational efficiency in a competitive generics business. Durable margins provide earnings resilience across cycles and create room for reinvestment, debt servicing and capital allocation.
Conservative Balance SheetVery low leverage delivers financial flexibility for capex, regulatory compliance and M&A without material refinancing risk. A growing equity base and modest debt levels reduce insolvency risk and permit opportunistic investment when markets or acquisition targets arise.
Bears Say
Gross Margin CompressionA sharp drop in gross margin signals structural pressure from input costs, pricing erosion, or adverse product mix. If sustained, this directly reduces operating leverage and free cash generation, forcing either cost cutting, price increases or margin dilution across product lines.
Inconsistent Cash ConversionIntermittent conversion of earnings to cash creates uncertainty around funding for capex, working capital and shareholder returns. Even with a FY2026 rebound, persistent volatility in cash conversion raises refinancing and liquidity planning risk over a multi-month horizon.
Rising Debt Vs Earlier YearsAn upward trend in debt, even from a low base, warrants monitoring: continued increases could erode the company’s conservative financing cushion, raise interest exposure and constrain flexibility for regulatory investments or acquisitions if cash generation weakens.
Marksans Pharma Limited News
MARKSANS FAQ
What was Marksans Pharma Limited’s price range in the past 12 months?
Marksans Pharma Limited lowest stock price was ₹155.50 and its highest was ₹270.60 in the past 12 months.
What is Marksans Pharma Limited’s market cap?
Marksans Pharma Limited’s market cap is ₹111.93B.
When is Marksans Pharma Limited’s upcoming earnings report date?
Marksans Pharma Limited’s upcoming earnings report date is Aug 07, 2026 which is in 57 days.
How were Marksans Pharma Limited’s earnings last quarter?
Marksans Pharma Limited released its earnings results on May 26, 2026. The company reported ₹3.25 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.25.
Is Marksans Pharma Limited overvalued?
According to Wall Street analysts Marksans Pharma Limited’s price is currently Overvalued.
Does Marksans Pharma Limited pay dividends?
Marksans Pharma Limited pays a Annually dividend of ₹0.8 which represents an annual dividend yield of 0.44%. See more information on Marksans Pharma Limited dividends here
What is Marksans Pharma Limited’s EPS estimate?
Marksans Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marksans Pharma Limited have?
Marksans Pharma Limited has 453,163,760 shares outstanding.
What happened to Marksans Pharma Limited’s price movement after its last earnings report?
Marksans Pharma Limited reported an EPS of ₹3.25 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.528%.
Which hedge fund is a major shareholder of Marksans Pharma Limited?
Currently, no hedge funds are holding shares in IN:MARKSANS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marksans Pharma Limited
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―
Sanofi India Limited
―